Amgen AMGN

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$6.18 (+1.94%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Amgen (AMGN)
    Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $324.86

    • Market Cap

      $174.27 Billion

    • Price-Earnings Ratio

      41.17

    • Total Outstanding Shares

      536.44 Million Shares

    • Total Employees

      26,700

    • Dividend

      $2.38 Per Share Quarterly

    • IPO Date

      June 17, 1983

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      One amgen center drive, Thousand oaks, CA, 91320

    • Homepage

      https://www.amgen.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$-5.25 Billion
    Net Cash Flow From Financing Activities, Continuing$-5.25 Billion
    Net Cash Flow, Continuing$-25.73 Billion
    Net Cash Flow From Investing Activities, Continuing$-27.73 Billion
    Net Cash Flow From Investing Activities$-27.73 Billion
    Net Cash Flow From Operating Activities$7.26 Billion

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Gross Profit$19.68 Billion
    Operating Expenses$13.46 Billion
    Income/Loss Before Equity Method Investments$4.68 Billion
    Net Income/Loss$4.23 Billion
    Basic Earnings Per Share$7.89
    Operating Income/Loss$6.22 Billion

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$4.02 Billion
    Other Comprehensive Income/Loss$-2.70 Billion
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss Attributable To Parent$-210 Million
    Comprehensive Income/Loss$4.02 Billion

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity Attributable To Noncontrolling Interest$0
    Other Non-current Assets$29.04 Billion
    Equity$7.53 Billion
    Other Non-current Liabilities$2.65 Billion
    Accounts Payable$2.15 Billion
    Inventory$7.36 Billion

    Historical Dividends

    Current dividend: $2.38 Per Share Quarterly
    Announcement DatePayment DateRecord DateAmountFrequency
    Mar 4, 2025Jun 6, 2025May 16, 2025$2.38Quarterly
    Dec 10, 2024Mar 7, 2025Feb 14, 2025$2.38Quarterly
    Oct 25, 2024Dec 9, 2024Nov 18, 2024$2.25Quarterly
    Aug 2, 2024Sep 6, 2024Aug 16, 2024$2.25Quarterly
    Mar 6, 2024Jun 7, 2024May 17, 2024$2.25Quarterly
    Dec 12, 2023Mar 7, 2024Feb 16, 2024$2.25Quarterly

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AMGN from trusted financial sources

      Related Companies

      Additional publicly traded companies similar to Amgen (AMGN)
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.